T-Therapeutics is a next-generation T cell receptor (TCR) company spun out from the University of Cambridge. The company was created to harness the power of T cell biology, to create safe and effective treatments for cancer and autoimmune disease. T-Therapeutics is developing a pipeline of first-in-class drugs that are intended to become transformative medicines, reshaping the clinical landscape for patients with cancer or autoimmune diseases.
Leadership & Board
Current Number of Employees65
Current LinkedIn Followers7,732
Latest Estimated Valuation
Estimated Valuation―
Estimated Valuation―
Total Amount Raised$91M
Total Amount Raised$91M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$91M
Latest Funding Amount$91M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation―
Post-Money Valuation―
Employee Trend
T-Therapeutics had 65 employees as of September 28, 2026. The number of employees increased by 1 (1.56%) week-over-week.
65Latest Employee Count
1(1.56%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.
Social Trend
T-Therapeutics had 7,732 followers as of September 28, 2026. The number of followers increased by 46 (0.60%) week-over-week.
7,732Latest Followers Count
46(0.60%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.